Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China
· Delayed Price · Currency is CNY 23.34
+0.41 (1.79%)
Mar 10, 2026, 1:14 PM CST
SHA:688298 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | -529.02 | -397.58 | 2,068 | 4,920 | Upgrade
|
| Depreciation & Amortization | - | 204.24 | 165.49 | 86.56 | 37.31 | Upgrade
|
| Other Amortization | - | 24.12 | 18 | 8.51 | 2.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0.99 | 0.18 | 0.01 | -0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 81.75 | 63.86 | 366.58 | 0.05 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -24.6 | -48.85 | -7.66 | -11.22 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 30.1 | 30.17 | -6.44 | 32.55 | Upgrade
|
| Other Operating Activities | - | -8.24 | 96.57 | 378.84 | 109.18 | Upgrade
|
| Change in Accounts Receivable | - | -109.37 | 210.28 | 825.4 | -692.05 | Upgrade
|
| Change in Inventory | - | 1.91 | -86.23 | -775.13 | -98.7 | Upgrade
|
| Change in Accounts Payable | - | -11.52 | -1,670 | 172.34 | 928.52 | Upgrade
|
| Change in Other Net Operating Assets | - | 15.78 | - | - | - | Upgrade
|
| Operating Cash Flow | - | -348.33 | -1,646 | 2,996 | 5,204 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | -42.43% | 190.67% | Upgrade
|
| Capital Expenditures | - | -924.09 | -996.05 | -1,052 | -507.87 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 7.51 | 0.81 | 2.58 | 1.79 | Upgrade
|
| Cash Acquisitions | - | -320.76 | -78.52 | -184.87 | -43.71 | Upgrade
|
| Investment in Securities | - | 678.26 | 81.54 | -1,076 | 228.15 | Upgrade
|
| Other Investing Activities | - | -111.06 | -1,126 | -65.22 | - | Upgrade
|
| Investing Cash Flow | - | -670.15 | -2,118 | -2,376 | -321.64 | Upgrade
|
| Long-Term Debt Issued | - | 300.75 | 772 | 50 | - | Upgrade
|
| Total Debt Issued | - | 300.75 | 772 | 50 | - | Upgrade
|
| Long-Term Debt Repaid | - | -459.27 | -331.82 | -6.21 | -6.97 | Upgrade
|
| Total Debt Repaid | - | -459.27 | -331.82 | -6.21 | -6.97 | Upgrade
|
| Net Debt Issued (Repaid) | - | -158.52 | 440.18 | 43.79 | -6.97 | Upgrade
|
| Repurchase of Common Stock | - | -276.95 | - | - | - | Upgrade
|
| Common Dividends Paid | - | -16.63 | -351.14 | -742.04 | -504.67 | Upgrade
|
| Other Financing Activities | - | 0.36 | -39.51 | - | 2.47 | Upgrade
|
| Financing Cash Flow | - | -451.74 | 49.54 | -698.25 | -509.17 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 51.89 | 85.85 | 536.65 | -75.44 | Upgrade
|
| Net Cash Flow | - | -1,418 | -3,628 | 458.62 | 4,298 | Upgrade
|
| Free Cash Flow | - | -1,272 | -2,642 | 1,944 | 4,696 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -58.60% | 182.32% | Upgrade
|
| Free Cash Flow Margin | - | -153.69% | -322.09% | 22.17% | 46.18% | Upgrade
|
| Free Cash Flow Per Share | - | -6.47 | -13.09 | 9.64 | 23.29 | Upgrade
|
| Cash Income Tax Paid | - | -13.59 | -24.31 | 1,112 | 260.08 | Upgrade
|
| Levered Free Cash Flow | - | -1,255 | -2,379 | 1,513 | 3,361 | Upgrade
|
| Unlevered Free Cash Flow | - | -1,243 | -2,368 | 1,517 | 3,362 | Upgrade
|
| Change in Working Capital | - | -125.68 | -1,573 | 101.82 | 113.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.